Mechanisms of decay of toxic CUGn RNA in DM1 patients

DM1 患者中有毒 CUGn RNA 的衰减机制

基本信息

  • 批准号:
    7620081
  • 负责人:
  • 金额:
    $ 7.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-05-15 至 2011-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Myotonic Dystrophy 1 (DM1) is a complex, inherited, neuro-muscular disease without cure. DM1 is caused by an expansion of untranslated CTG repeats within the 3' UTR of DMPK gene located on the chromosome 19q. We and others found that DM1 mutation causes a disease through accumulation of untranslated RNA CUG repeats which disrupt RNA processing in patients' cells. Mutant DMPK mRNA containing expanded CUG repeats is forming nuclear foci, disassembly of which is expected to reverse the disease phenotype. It is also expected that degradation of mutant DMPK mRNA would reduce toxicity of CUG repeats. However, latest data suggest that the short products of degradation of the mutant DMPK mRNA are more toxic than un-degraded RNA. (1) It has been recently found that the accumulation of multiple copies of short CUG repeats of normal size in mice produced DM1-like phenotype (myotonia, muscular dystrophy and cardiac conduction defects), while mice with low number of copies of long CUG repeats organized in nuclear foci were asymptomatic; (2) Our recent data on the mechanism of DM2, which is associated with expansion of untranslated CCTG repeats showed that accumulation of normal size of RNA CCUG repeats leads to DM2-specific abnormalities. Based on these data, we hypothesize that toxicity of CUG repeat expansion in DM1 patients is associated with the products of degradation of the mutant DMPK mRNA, while undegraded mutant RNA is not toxic. To examine this hypothesis, we propose to compare the effect of un-degraded (stable) and decayed CUG transcripts on DM1-specific pattern of RNA processing (translation and splicing). These studies are designed in Specific Aim 1. Time curve for mutant CUGn RNA decay will be determined after transcription pulse of CUGn-containing transcripts using tet-responsive promoter. We will examine whether nuclear CUG foci are formed by non-degraded or degraded mutant CUG repeats and whether CUG foci formation increases or reduces toxicity of CUGn repeats. We will determine the period of life of CUGn mutant transcript during which it has highest toxicity. The mechanisms regulating stability and decay of normal and mutant DMPK mRNA will be examined in Specific Aim 2. Regulatory regions within the 3' UTR of DMPK controlling DMPK mRNA turnover will be determined. Protein factors regulating normal and mutant DMPK mRNA stability and decay will be identified. The results of this study will identify status of mutant CUGn repeats when these transcripts become toxic and will help to develop approach to reduce CUGn RNA toxicity by controlling decay of the mutant DMPK mRNA. PUBLIC HEALTH RELEVANCE. DM1 is a devastating disease associated with toxicity of untranslated RNA containing repetitive CUG repeats. This project will identify status of CUG repeats when CUG repeats become toxic and will develop approach to reduce toxicity of these repeats at the level of CUGn RNA stability.
描述(申请人提供):强直性肌营养不良症1(DM1)是一种复杂的、遗传的、无法治愈的神经肌肉疾病。DM1是由位于染色体19q的DMPK基因3‘非编码区内未翻译的CTG重复序列的扩增引起的。我们和其他人发现,DM1突变通过积累未翻译的RNA CUG重复而导致疾病,这会扰乱患者细胞中的RNA处理。含有扩展的CUG重复序列的突变的DMPK mRNA正在形成核灶,其分解有望逆转疾病的表型。预计突变的DMPK mRNA的降解将降低CUG重复序列的毒性。然而,最新的数据表明,突变的DMPK mRNA降解的短产物比未降解的RNA毒性更大。(1)最近发现,正常大小的短CUG重复序列在小鼠体内的多个拷贝的积累产生了DM1样表型(肌强直、肌营养不良和心脏传导缺陷),而在核病灶中组织的长CUG重复序列拷贝数低的小鼠没有症状;(2)我们最近对DM2的机制的研究数据表明,正常大小的RNA CCUG重复序列的积累会导致DM2特异的异常。根据这些数据,我们假设CUG重复扩增对DM1患者的毒性与突变DMPK mRNA降解的产物有关,而未降解的突变RNA是无毒的。为了验证这一假设,我们建议比较未降解(稳定)和腐烂的CUG转录本对DM1特定RNA处理模式(翻译和剪接)的影响。这些研究都是在特定的目标下设计的:1.突变的cugn RNA衰变的时间曲线将在含有cugn的转录本使用tet反应启动子的转录脉冲后确定。我们将研究核CUG焦点是由非降解的还是降解的突变CUG重复形成的,以及CUG焦点的形成是否增加或降低了CuGN重复的毒性。我们将确定CuGN突变转录本的生命周期,在此期间它具有最高的毒性。调节正常和突变DMPK mRNA稳定性和衰变的机制将在特定的目标2中进行研究。DMPK 3‘非编码区内调控DMPK mRNA周转的区域将被确定。调节正常和突变的DMPK mRNA稳定性和衰败的蛋白质因子将被识别。本研究的结果将确定突变的Cugn重复序列在这些转录物变毒时的状态,并将有助于开发通过控制突变的DMPK mRNA的衰退来降低Cugn RNA毒性的方法。与公共卫生相关。DM1是一种与含有重复CUG重复序列的未翻译RNA的毒性有关的破坏性疾病。该项目将确定当CUG重复序列变得有毒时CUG重复序列的状态,并将开发在Cugn RNA稳定性水平上降低这些重复序列毒性的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LUBOV T TIMCHENKO其他文献

LUBOV T TIMCHENKO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LUBOV T TIMCHENKO', 18)}}的其他基金

CNS in Congenital DM1: Pathogenesis and Therapeutic Opportunities
先天性 DM1 中的中枢神经系统:发病机制和治疗机会
  • 批准号:
    10089488
  • 财政年份:
    2020
  • 资助金额:
    $ 7.68万
  • 项目类别:
CNS in Congenital DM1: Pathogenesis and Therapeutic Opportunities
先天性 DM1 中的中枢神经系统:发病机制和治疗机会
  • 批准号:
    10553142
  • 财政年份:
    2020
  • 资助金额:
    $ 7.68万
  • 项目类别:
GSK3 beta study in patients with Myotonic Dystrophy 1
强直性肌营养不良患者的 GSK3 beta 研究 1
  • 批准号:
    10593112
  • 财政年份:
    2019
  • 资助金额:
    $ 7.68万
  • 项目类别:
GSK3 beta study in patients with Myotonic Dystrophy 1
强直性肌营养不良患者的 GSK3 beta 研究 1
  • 批准号:
    10326843
  • 财政年份:
    2019
  • 资助金额:
    $ 7.68万
  • 项目类别:
GSK3 beta study in patients with Myotonic Dystrophy 1
强直性肌营养不良患者的 GSK3 beta 研究 1
  • 批准号:
    10087889
  • 财政年份:
    2019
  • 资助金额:
    $ 7.68万
  • 项目类别:
Inhibition of GSK3 beta as potential therapy for DM1
抑制 GSK3 beta 作为 DM1 的潜在疗法
  • 批准号:
    8930071
  • 财政年份:
    2014
  • 资助金额:
    $ 7.68万
  • 项目类别:
Inhibition of GSK3 beta as potential therapy for DM1
抑制 GSK3 beta 作为 DM1 的潜在疗法
  • 批准号:
    8635126
  • 财政年份:
    2014
  • 资助金额:
    $ 7.68万
  • 项目类别:
The toxicity of the RNA CGG repeats in FXTAS
FXTAS 中 RNA CGG 重复序列的毒性
  • 批准号:
    8897690
  • 财政年份:
    2012
  • 资助金额:
    $ 7.68万
  • 项目类别:
The toxicity of the RNA CGG repeats in FXTAS
FXTAS 中 RNA CGG 重复序列的毒性
  • 批准号:
    8442154
  • 财政年份:
    2012
  • 资助金额:
    $ 7.68万
  • 项目类别:
The toxicity of the RNA CGG repeats in FXTAS
FXTAS 中 RNA CGG 重复序列的毒性
  • 批准号:
    8536413
  • 财政年份:
    2012
  • 资助金额:
    $ 7.68万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了